Skip to main content
main-content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Oral Health 1/2015

Plectin as a prognostic marker in non-metastatic oral squamous cell carcinoma

Zeitschrift:
BMC Oral Health > Ausgabe 1/2015
Autoren:
Oddveig G. Rikardsen, Synnøve N. Magnussen, Gunbjørg Svineng, Elin Hadler-Olsen, Lars Uhlin-Hansen, Sonja E. Steigen
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

OGR collected the material, carried out immunohistochemical and immunofluorescence staining, interpreted data, performed statistical analysis, and drafted the manuscript. SNM carried out immunohistochemical staining, interpreted data and drafted the manuscript. Gs and EHO participated in the design of the study, contributed to interpretation of data, and critically revised the manuscript. LUH conceived the design of the study, contributed to interpretation of data, and critically revised the manuscript. SES participated in the design of the study, contributed to interpretation of data, performed statistical analysis, and revised the manuscript critically. All authors read and approved the final manuscript.

Abstract

Background

Oral squamous cell carcinoma (OSCC) is associated with a poor 5-year survival rate. In general, patients diagnosed with small tumors have a fairly good prognosis, but some small tumors have an aggressive behavior leading to early death. There are at present no reliable prognostic biomarkers for oral cancers. Thus, to optimize treatment for the individual patient, there is a need for biomarkers that can predict tumor behavior.

Method

In the present study the potential prognostic value of plectin was evaluated by a tissue microarray (TMA) based immunohistochemical analysis of primary tumor tissue obtained from a North Norwegian cohort of 115 patients diagnosed with OSCC. The expression of plectin was compared with clinicopathological variables and 5 year survival.

Results

The statistical analysis revealed that low expression of plectin in the tumor cells predicted a favorable outcome for patients with non-metastatic disease (p = 0.008). Furthermore, the expression of plectin was found to correlate (p = 0.01) with the expression of uPAR, which we have previously found to be a potential prognostic marker for T1N0 tumors.

Conclusions

Our results indicate that low expression of plectin predicts a favorable outcome for patients with non-metastatic OSCC and the expression level of plectin may therefore be used in the treatment stratification for patients with early stage disease.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Oral Health 1/2015 Zur Ausgabe

Neu im Fachgebiet Zahnmedizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise